Buchumschlag

Significance of Evaluating Tumor Markers in the Oncological Criteria for Resectability in Hepatocellular Carcinoma

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Yuya Miura, Ryo Ashida, Yukiyasu Okamura, Katsuhisa Ohgi, Yoshiyasu Kato, Shimpei Otsuka, Hideyuki Dei, Rui Sato, Katsuhiko Uesaka, Teiichi Sugiura
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Hepatology Research
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Tumor Mutational Concordance and Recurrence Timing in Hepatocellular Carcinoma
von: Yuya Miura, et al.
Veröffentlicht: (2026)

Rectus abdominis muscle wrap for effective control of hepatic artery bleeding
von: Teiichi Sugiura, et al.
Veröffentlicht: (2025)

Association Between the Degree of Arterial Contact Angle and Survival in Patients With Borderline Resectable Pancreatic Cancer
von: Katsuhisa Ohgi, et al.
Veröffentlicht: (2025)

Subdivision of pT1N0 (American Joint Committee on Cancer 8th edition) distal cholangiocarcinoma for adjuvant chemotherapy consideration
von: Shimpei Otsuka, et al.
Veröffentlicht: (2024)

Utility of Oncological Resectability Criteria in Recurrent Hepatocellular Carcinoma After Hepatectomy
von: Nobuaki Ishihara, et al.
Veröffentlicht: (2025)

Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade
von: Hideyuki Tamai, et al.
Veröffentlicht: (2025)

Predictive factors of actual 5‐y recurrence‐free survival after upfront surgery for resectable pancreatic cancer
von: Masao Uemura, et al.
Veröffentlicht: (2024)

Clinical Impact of Recurrence Beyond the Milan Criteria After Curative Resection of Hepatocellular Carcinoma
von: Takeshi Terashima, et al.
Veröffentlicht: (2025)

Diagnostic Performance of Serum Autotaxin for Staging Liver Fibrosis: A Comparative Study With Other Noninvasive Liver Fibrosis Tests in Chronic Liver Disease
von: Hideyuki Tamai, et al.
Veröffentlicht: (2025)

Individualized Prognostication Based on Deep‐Learning Models Using Computed Tomography as an Imaging Biomarker After Hepatocellular Carcinoma Resection
von: Hiroji Shinkawa, et al.
Veröffentlicht: (2025)

Novel Potential Markers of Metabolic Dysfunction–Associated Steatohepatitis Prone to Hepatocellular Carcinoma
von: Chen Ling, et al.
Veröffentlicht: (2026)

Mitochondrial Oxidative Stress in Circulating Leukocytes as a Prognostic Marker in Hepatocellular Carcinoma
von: Víctor Merino, et al.
Veröffentlicht: (2025)

Surgical Resections for Hepatocellular Carcinomas Arising From Fontan‐Associated Liver Disease; Open, Laparoscopic and Robotic Hepatectomies
von: Takashi Motomura, et al.
Veröffentlicht: (2026)

Impact of Surgical Resection on Hepatocellular Carcinoma Following Systemic Drug Therapy: A Multicenter Retrospective Observational Study
von: Takamichi Ishii, et al.
Veröffentlicht: (2025)

The Roles and Clinical Significance of Major Hepatic‐Derived Metabolites in Hepatocellular Carcinoma
von: Rui Sun, et al.
Veröffentlicht: (2025)

Comment on “Individualized Prognostication Based on Deep‐Learning Models Using Computed Tomography as an Imaging Biomarker After Hepatocellular Carcinoma Resection”
von: Minghai Shen, et al.
Veröffentlicht: (2025)

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
von: Keishi Ouchi, et al.
Veröffentlicht: (2026)

Circulating Tumor Cells as Diagnostic and Therapeutic Biomarkers in Hepatocellular Carcinoma: Advancing Precision Oncology Through Liquid Biopsy
von: Mutaz Jamal Al‐khreisat, et al.
Veröffentlicht: (2026)

Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early‐Stage Viral Disease
von: Kazuya Kariyama, et al.
Veröffentlicht: (2025)

Adjuvant Transarterial Chemoembolization After Truly Curative Resection Does Not Improve Survival of Patients With Hepatocellular Carcinoma at High Risk of Recurrence: A Target Trial Emulation Study
von: Jia‐Yong Su, et al.
Veröffentlicht: (2025)

Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma
von: Kazuya Kariyama, et al.
Veröffentlicht: (2026)

Response to “Letter to the Editor: Pre‐Treatment Liver Stiffness is a Stronger Predictor of Hepatocellular Carcinoma Development Than Post‐Treatment Liver Stiffness After Hepatitis C Virus Eradication”
von: Takuma Nakatsuka, et al.
Veröffentlicht: (2025)

Expression of PCED1A in Hepatocellular Carcinoma and Colorectal Cancer and Its Relationship with Immune Infiltration: Potential as a Diagnostic Marker
von: Meiling Wang, et al.
Veröffentlicht: (2025)

The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy
von: Van Khanh Nguyen, et al.
Veröffentlicht: (2026)

The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis
von: Ryo Sato, et al.
Veröffentlicht: (2025)

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab
von: Kazunari Tanaka, et al.
Veröffentlicht: (2026)

Validation of Liquid Biopsy Using a Methylated SEPT9 Assay and Integrated Index for Detecting Hepatocellular Carcinoma
von: Issei Saeki, et al.
Veröffentlicht: (2025)

Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First‐Line Therapy for Intermediate‐Stage Hepatocellular Carcinoma Beyond the Up‐to‐Seven Criteria
von: Takashi Niizeki, et al.
Veröffentlicht: (2025)

Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma
von: Shinsuke Uchikawa, et al.
Veröffentlicht: (2024)

Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
von: Tomomitsu Matono, et al.
Veröffentlicht: (2025)

Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma
von: Yuichiro Suzuki, et al.
Veröffentlicht: (2025)

A Novel Diagnostic Approach for Hepatocellular Carcinoma Using Glycosylated Ferritin
von: Akiyo Ishiguro, et al.
Veröffentlicht: (2026)

Aspirin Use and Hepatocellular Carcinoma Risk
von: Kuan‐Fu Liao, et al.
Veröffentlicht: (2025)

Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child–Pugh Class B: A Real‐World Study
von: Hideko Ohama, et al.
Veröffentlicht: (2026)

Progressive Sarcopenia as a Prognostic Marker in the Era of Immunotherapy
von: Takeshi Okamoto, et al.
Veröffentlicht: (2025)

Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
von: Takanori Ito, et al.
Veröffentlicht: (2025)

Refining Surgical Candidate Selection After Systemic Therapy in Advanced Hepatocellular Carcinoma
von: Jinzhen Huang, et al.
Veröffentlicht: (2025)

Lymphocyte‐to‐Monocyte Ratio as a Practical Biomarker for Immunotherapy Response in Hepatocellular Carcinoma
von: Satoshi Tanaka
Veröffentlicht: (2025)

Subcutaneous Adipose Tissue Accumulation is Associated With an Improved Prognosis in Patients With Hepatocellular Carcinoma
von: Kenji Imai, et al.
Veröffentlicht: (2026)

Dual Escape From Disulfidptosis and Ferroptosis Drives Highly Aggressive, Hypermetabolic Hepatocellular Carcinoma
von: Junya Mita, et al.
Veröffentlicht: (2026)